Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position

Stock Track

Feb 06

Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.

The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which exceeded analyst expectations. Immunovant reported a quarterly loss of $0.61 per share, beating the consensus estimate of $0.71 by 13.72% and marking a 19.74% improvement over the loss of $0.76 per share from the same period last year. The company's net loss of $110.64 million also came in better than the anticipated $125.06 million.

Investors were further encouraged by Immunovant's robust financial position. As of December 31, 2025, the clinical-stage immunology company reported cash and cash equivalents of $994.5 million. This strong balance sheet was recently bolstered by a $550 million financing round, extending the company's cash runway to support the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track, with topline data expected in 2026 and 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184858608"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184858608\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184858608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184858608","market":"nz","top_or_hot":-1,"title":"Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position","media":"Stock Track","content":"<p>Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.</p><p>The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which exceeded analyst expectations. Immunovant reported a quarterly loss of $0.61 per share, beating the consensus estimate of $0.71 by 13.72% and marking a 19.74% improvement over the loss of $0.76 per share from the same period last year. The company's net loss of $110.64 million also came in better than the anticipated $125.06 million.</p><p>Investors were further encouraged by Immunovant's robust financial position. As of December 31, 2025, the clinical-stage immunology company reported cash and cash equivalents of $994.5 million. This strong balance sheet was recently bolstered by a $550 million financing round, extending the company's cash runway to support the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track, with topline data expected in 2026 and 2027.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunovant Soars 11.72% Intraday on Better-Than-Expected Q3 Results and Strong Financial Position\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.</p><p>The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which exceeded analyst expectations. Immunovant reported a quarterly loss of $0.61 per share, beating the consensus estimate of $0.71 by 13.72% and marking a 19.74% improvement over the loss of $0.76 per share from the same period last year. The company's net loss of $110.64 million also came in better than the anticipated $125.06 million.</p><p>Investors were further encouraged by Immunovant's robust financial position. As of December 31, 2025, the clinical-stage immunology company reported cash and cash equivalents of $994.5 million. This strong balance sheet was recently bolstered by a $550 million financing round, extending the company's cash runway to support the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track, with topline data expected in 2026 and 2027.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMVT","symbol_name":"Immunovant, Inc.","start_time":0,"source_url":"","article_id":"1184858608","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184858608","pubTimestamp":1770388745,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMVT":"Immunovant, Inc."},"translate_title":"个股追踪|Immunovant盘中大涨11.72%，Q3业绩好于预期，财务状况强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMVT":1},"content_text":"Immunovant, Inc. (IMVT) saw its stock price soar 11.72% during intraday trading on Friday.The significant surge follows the company's release of its third-quarter fiscal 2025 financial results, which exceeded analyst expectations. Immunovant reported a quarterly loss of $0.61 per share, beating the consensus estimate of $0.71 by 13.72% and marking a 19.74% improvement over the loss of $0.76 per share from the same period last year. The company's net loss of $110.64 million also came in better than the anticipated $125.06 million.Investors were further encouraged by Immunovant's robust financial position. As of December 31, 2025, the clinical-stage immunology company reported cash and cash equivalents of $994.5 million. This strong balance sheet was recently bolstered by a $550 million financing round, extending the company's cash runway to support the potential commercial launch of its lead candidate, IMVT-1402, for Graves' disease. Clinical trials for IMVT-1402 across multiple indications remain on track, with topline data expected in 2026 and 2027.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}